Authors
Lillian M Smyth, Sarina A Piha-Paul, Helen H Won, Alison M Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I Shapiro, Dejan Juric, Ingrid A Mayer, Carlos L Arteaga, Macarena I de la Fuente, Adam M Brufksy, Iben Spanggaard, Morten Mau-Sørensen, Monica Arnedos, Victor Moreno, Valentina Boni, Joohyuk Sohn, Lee S Schwartzberg, Xavier Gonzàlez-Farré, Andrés Cervantes, François-Clement Bidard, Alexander N Gorelick, Richard B Lanman, Rebecca J Nagy, Gary A Ulaner, Sarat Chandarlapaty, Komal Jhaveri, Elena I Gavrila, Catherine Zimel, S Duygu Selcuklu, Myra Melcer, Aliaksandra Samoila, Yanyan Cai, Maurizio Scaltriti, Grace Mann, Feng Xu, Lisa D Eli, Melanie Dujka, Alshad S Lalani, Richard Bryce, José Baselga, Barry S Taylor, David B Solit, Funda Meric-Bernstam, David M Hyman
Publication date
2020/2/1
Journal
Cancer discovery
Volume
10
Issue
2
Pages
198-213
Publisher
American Association for Cancer Research
Description
HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of multiple HER2-activating events, as well as gatekeeper alterations, were observed at disease progression in a high proportion of patients deriving clinical benefit from neratinib. Collectively, these data …
Scholar articles
LM Smyth, SA Piha-Paul, HH Won, AM Schram… - Cancer discovery, 2020